International Conference on Neurology and Neuropharmacology
ICNNP
Official Invitation Letter Available
An official invitation letter will be provided upon successful registration for your participation in the conference.
Benefits of Registering as Listener
Access to All Conference Sessions
Plenary, keynote and parallel sessions
Networking Opportunities
Connect with global educators & researchers
Certificate of Participation
Digital certificate of participation
Invitation Letter Support
Official invitation letter after successful registration
Conference Kit / Digital Materials
E-proceedings & resource materials
Access to Keynote Sessions
Learn from leading experts & scholars
Conference Session Tracks
Aligned with UN Sustainable Development Goals
The conference's session tracks effectively support the following SDGs.
This track will explore the latest breakthroughs in neuropharmacology, focusing on novel drug formulations and their mechanisms of action. Emphasis will be placed on the translation of these advancements into clinical practice for neurological disorders.
SDG 3
SDG 4
This session will address the complexities involved in the development of central nervous system drugs, including regulatory hurdles and market access. Discussions will highlight innovative strategies to overcome these challenges and expedite drug approval.
SDG 3
SDG 9
This track will delve into the pharmacological properties of neuroprotective agents and their potential applications in various neurological conditions. Presentations will focus on both preclinical and clinical studies that demonstrate efficacy and safety.
SDG 3
SDG 4
This session will examine the role of pharmacogenomics in personalizing treatment strategies for neurological disorders. Attendees will learn how genetic variations influence drug response and the implications for clinical practice.
SDG 3
SDG 9
This track will provide insights into the safety profiles and efficacy of current neurological therapeutics. Expert speakers will discuss methodologies for assessing drug safety and the importance of post-marketing surveillance.
SDG 3
SDG 9
This session will highlight cutting-edge methodologies in drug discovery specifically tailored for neurological applications. Topics will include high-throughput screening, in silico modeling, and the role of artificial intelligence in drug development.
SDG 3
SDG 9
This track will focus on the clinical pharmacology aspects of neurological treatments, including dosing strategies and therapeutic monitoring. Participants will discuss case studies that illustrate the complexities of managing neurological patients.
SDG 3
SDG 4
This session will explore current trends in neurotherapeutics, including emerging therapies and their potential impact on patient outcomes. Future directions in the field will also be discussed, emphasizing the need for continued research.
SDG 3
SDG 9
This track will present evidence-based treatment strategies for various neurological disorders, integrating pharmacological and non-pharmacological interventions. Participants will engage in discussions about optimizing patient care through multidisciplinary approaches.
SDG 3
SDG 4
This session will highlight the importance of translational research in neuropharmacology, showcasing studies that bridge laboratory findings with clinical applications. Emphasis will be placed on collaborative efforts between researchers and clinicians.
SDG 3
SDG 4
This track will provide a forward-looking perspective on the future of neurology and neuropharmacology, discussing anticipated advancements and emerging challenges. Experts will share their visions for the evolution of therapeutic approaches in the field.
SDG 3
SDG 9